Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and 18F-FDG-PET/CT in correlation to clinical pathologic outcome.

Jreige M, Dunet V, Letovanec I, Prior JO, Meuli RA, Beigelman-Aubry C, Schaefer N.

J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575. [Epub ahead of print]

PMID:
31227574
2.

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.

PMID:
31214790
3.

Diagnostic Performance of PET or PET/CT Using 18F-FDG Labeled White Blood Cells in Infectious Diseases: A Systematic Review and a Bivariate Meta-Analysis.

Meyer M, Testart N, Jreige M, Kamani C, Moshebah M, Muoio B, Nicod-Lalonde M, Schaefer N, Giovanella L, Prior JO, Treglia G.

Diagnostics (Basel). 2019 Jun 15;9(2). pii: E60. doi: 10.3390/diagnostics9020060. Review.

4.

Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.

Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N.

Oncotarget. 2017 Dec 19;9(4):4549-4558. doi: 10.18632/oncotarget.23423. eCollection 2018 Jan 12.

5.

18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23.

PMID:
28233086
6.

PET/CT Scanner and Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Diffuse Large B-Cell Lymphoma.

El Karak F, Bou-Orm IR, Ghosn M, Kattan J, Farhat F, Ibrahim T, Jreige M, El Cheikh J, Haidar M.

PLoS One. 2017 Jan 18;12(1):e0170299. doi: 10.1371/journal.pone.0170299. eCollection 2017.

7.

Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry.

Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, Mitsakis P, Silva-Monteiro M, Gnesin S, Lalonde MN, Duran R, Prior JO, Schaefer N.

J Nucl Med. 2017 Aug;58(8):1334-1340. doi: 10.2967/jnumed.116.184713. Epub 2017 Jan 12.

8.

The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.

Haidar M, Shamseddine A, Panagiotidis E, Jreige M, Mukherji D, Assi R, Abousaid R, Ibrahim T, Haddad MM, Vinjamuri S.

Nucl Med Commun. 2017 Feb;38(2):170-177. doi: 10.1097/MNM.0000000000000623.

PMID:
27922538
9.

68Ga-NODAGA-RGDyK PET/CT Imaging in Esophageal Cancer: First-in-Human Imaging.

Van Der Gucht A, Pomoni A, Jreige M, Allemann P, Prior JO.

Clin Nucl Med. 2016 Nov;41(11):e491-e492.

10.

Diffusion-weighted whole-body imaging with background body signal suppression in Castleman disease.

Khalil G, Gaspard D, Jreige M, Nawfal G.

Clin Imaging. 2013 Jan-Feb;37(1):185-8. doi: 10.1016/j.clinimag.2012.02.015. Epub 2012 Jun 8.

PMID:
23206632

Supplemental Content

Loading ...
Support Center